| Overview |
| Management |
| Scientific advisory board |
| Publications |
| News |
| The Ubiquitin System |
| Proteologics Discovery Platfrom |
| Target Discovery and Validation |
| Assay Development |
| Drug Discovery |
| Drug Development |
| Link |
| Antiviral programs |
| Anticancer programs |
| Collaborations |
Teva Pharmaceutical Industries Ltd.
Proteologics entered into an R&D collaboration with Teva Pharmaceutical Industries Ltd. to promote two anti-cancer projects. The projects follow different directions: Proudly, we have reached the deadlines in record times in both projects - far preceding the scheduled timeframe. In addition to Teva, we have also formed collaborations with several international academic institutions like the City of Hope Research Hospital in California, US and the Erlangen University in GermanyNew collaborations
There is a known causative link between the ubiquitin system and many other major human diseases including neuro-degenerative conditions (such as Alzheimer's and Parkinson's diseases), viral infections and immune disorders. Based on Proteologics' leading position in ubiquitin based target and drug discovery, additional research programs in flu & CNS diseases are currently under discussion with potential corporate partners.
Collaborations with academy
Dr. Ulrich Schubert
Ever since HIV was first shown to depend on the ubiquitin system for its biogenesis (Schubert, 2000 ), Proteologics has been investigating the field with an aim of developing novel anti-HIV therapeutics. The company joined forces with world leaders of the ubiquitin and virology research. The company formed a long-lasting partnership with Dr. Schubert from Erlangen University, GermanyDr. John Rossi
In August 2005 Proteologics entered into anti-HIV gene therapy research collaboration with the laboratory of Dr. John. J. Rossi., chair, Division of Molecular Biology at City of Hope National Medical Center, Calif. Under the collaboration Dr. Rossi will develop specific RNAi molecules against ubiquitin targets, delivered by Proteologics, and measure the impact on HIV replication.Dr. Eran Bacharach
In 2006 Proteologics has entered into a research collaboration with the laboratory of Dr. Eran Bacharach at the Tel-Aviv University, Tel-Aviv. Under the collaboration Dr. Bacharach will research the mechanism of action of one of Proteologics' targets
